港股開市 | 恒指高開0.53%，小米績後高開1.25%，康希諾生物-B連升11天
香港恒生指數開市上升128.96點，升幅0.53%，報24528.91點；恒生國企指數開市上升33.54點，升幅0.34%，報9931.54點；恒生紅籌指數開市上升24.88點，升幅0.66%，報3817.76點。
【藍籌股】
50隻恒指成分股，36隻開升，瑞聲科技高開1.71%，為表現最佳藍籌。
【異動板塊】
汽車股開市普遍上升，北京汽車開升2.02%，比亞迪股份、長城汽車升超1%；吉利汽車開升0.16%，廣汽集團開升0.7%，華晨中國開升0.56%，中國乘聯會稱，5月乘用車零售明顯回暖，第二周銷量同比降幅縮小至3% 。
消費股開市普升，九毛九開升0.63%，李寧開升0.57%，中國總理李克強主持召開會議稱，中國將完善疫情常態化防控， 促進消費和經濟加快回升。
【個股方面】
小米集團-W高開1.25%，小米集團一季度淨利潤21.63億元，遠超市場預期，營收為497.02億元，亦超市場預期，並獲中金調升目標價。
康希諾生物-B高開3.82%，報255.4港元，已連續11個交易日上升，今年以來，股價升幅高達333%。今日，康希諾生物-B和加拿大的Precision NanoSystems(PNI)公司聯合宣佈，雙方達成協議，將利用PNI公司的獨有RNA疫苗技術平台，開發基於mRNA脂質納米顆粒(mRNA-LNP)技術的疫苗。
中國飛鶴高開0.3%，廣發證券給予公司2020年26倍PE，對應合理價值為15.91港元/股，首次覆蓋給予“買入”評級。
藥明生物低開2.69%，最大股東尋求通過配售股票至多融資8.26億美元。
次新股方面，“-B”字頭個股近期升勢如虹，沛嘉醫療-B高開1.02%，康方生物-B高開1.01%，諾誠健華-B高開0.99%。
免責聲明：本文所載的所有資料、資料等（「資料」）只供參考之用，不構銷售或建議任何投資、交易策略或金融產品的要約或招攬。本公司會盡力確保資料的準確性及可靠性, 但不保證該資料為準確無誤, 亦不承擔因任何不準確或遺漏而引起的損失或損害。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
